CEACAM6

Summary

CEACAM6 (CEA cell adhesion molecule 6, HGNC:1818) is a protein-coding gene on chromosome 19q13.2, encoding Cell adhesion molecule CEACAM6 (P40199). Cell surface glycoprotein that plays a role in cell adhesion and tumor progression.

This gene encodes a protein that belongs to the carcinoembryonic antigen (CEA) family whose members are glycosyl phosphatidyl inositol (GPI) anchored cell surface glycoproteins. Members of this family play a role in cell adhesion and are widely used as tumor markers in serum immunoassay determinations of carcinoma. This gene affects the sensitivity of tumor cells to adenovirus infection. The protein encoded by this gene acts as a receptor for adherent-invasive E. coli adhesion to the surface of ileal epithelial cells in patients with Crohn’s disease. This gene is clustered with genes and pseudogenes of the cell adhesion molecules subgroup of the CEA family on chromosome 19.

Source: NCBI Gene 4680 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cystic fibrosis (Supportive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 53 total
• GTEx eGene: eQTL in 8 tissues, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 35
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.91 (unconstrained)
• MANE Select transcript: NM_002483
• Notable: 53 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1818
Approved symbol	CEACAM6
Name	CEA cell adhesion molecule 6
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	CD66c, NCA-50/90
Ensembl gene	ENSG00000086548
Ensembl biotype	protein_coding
OMIM	163980
Entrez	4680

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

MANE Select: ENST00000199764

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 4: 1

ENST00000199764, ENST00000595740, ENST00000890871, ENST00000943164, ENST00001119190, ENST00001140243

RefSeq mRNA: 1 — MANE Select: NM_002483 NM_002483

CCDS: CCDS12585

Canonical transcript exons

ENST00000199764 — 6 exons

Exon	Start	End
ENSE00000842495	41766183	41766299
ENSE00001053047	41770802	41772211
ENSE00001806789	41755530	41755702
ENSE00002438901	41756600	41756959
ENSE00002477928	41761969	41762223
ENSE00002506588	41761249	41761527

Expression profiles

Bgee: expression breadth ubiquitous, 208 present calls, max score 99.94.

FANTOM5 (CAGE): breadth broad, TPM avg 7.6087 / max 1657.3322, expressed in 480 samples.

Highest expression (Bgee): pancreatic ductal cell, palpebral conjunctiva, nasal cavity epithelium, colonic mucosa, mucosa of sigmoid colon.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CEACAM6 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 8 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

9 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Esophagus Mucosa	eqtl	1.9e-05	-0.13	19:41802009:A:G
Minor Salivary Gland	eqtl	6.4e-03	-1.06	19:41474116:C:T
Nerve Tibial	eqtl	7.0e-03	+0.98	19:41312640:T:G
Adipose Subcutaneous	eqtl	1.8e-02	-0.70	19:41698003:G:A
Brain Cerebellar Hemisphere	eqtl	2.0e-02	+0.73	19:42445999:G:A
Skin Sun Exposed Lower leg	sqtl	2.4e-02	-0.90	19:41755328:G:A
Whole Blood	eqtl	3.1e-02	-0.09	19:41759235:A:G
Liver	eqtl	3.2e-02	-0.56	19:41237549:C:A
Heart Left Ventricle	eqtl	4.0e-02	-1.03	19:41116576:G:C

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
176057	7.0306	472
176058	0.3670	82
176059	0.1817	49
176056	0.0293	14

Top tissues by expression

showing 100 of 275 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.94	gold quality
palpebral conjunctiva	UBERON:0001812	99.87	gold quality
nasal cavity epithelium	UBERON:0005384	99.57	gold quality
colonic mucosa	UBERON:0000317	99.43	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.38	gold quality
esophagus squamous epithelium	UBERON:0006920	99.36	gold quality
lower lobe of lung	UBERON:0008949	99.36	gold quality
pharyngeal mucosa	UBERON:0000355	99.26	gold quality
epithelium of bronchus	UBERON:0002031	99.20	gold quality
bronchial epithelial cell	CL:0002328	99.19	gold quality
bronchus	UBERON:0002185	99.19	gold quality
trabecular bone tissue	UBERON:0002483	99.19	gold quality
epithelium of nasopharynx	UBERON:0001951	99.15	gold quality
nasopharynx	UBERON:0001728	99.13	gold quality
tongue squamous epithelium	UBERON:0006919	99.08	gold quality
oral cavity	UBERON:0000167	99.02	gold quality
urethra	UBERON:0000057	98.85	gold quality
epithelium of esophagus	UBERON:0001976	98.73	gold quality
jejunal mucosa	UBERON:0000399	98.65	gold quality
rectum	UBERON:0001052	98.59	gold quality
right lung	UBERON:0002167	98.50	gold quality
trachea	UBERON:0003126	98.37	gold quality
cervix epithelium	UBERON:0004801	98.05	gold quality
body of tongue	UBERON:0011876	98.05	gold quality
lower esophagus mucosa	UBERON:0035834	98.03	gold quality
mucosa of transverse colon	UBERON:0004991	97.93	gold quality
cervix squamous epithelium	UBERON:0006922	97.79	gold quality
upper lobe of lung	UBERON:0008948	97.74	gold quality
upper lobe of left lung	UBERON:0008952	97.60	gold quality
visceral pleura	UBERON:0002401	97.48	gold quality
gall bladder	UBERON:0002110	97.38	gold quality
squamous epithelium	UBERON:0006914	97.33	gold quality
bone marrow	UBERON:0002371	97.28	gold quality
tongue	UBERON:0001723	97.14	gold quality
islet of Langerhans	UBERON:0000006	97.02	gold quality
esophagus mucosa	UBERON:0002469	97.01	gold quality
ileal mucosa	UBERON:0000331	97.00	gold quality
epithelial cell of pancreas	CL:0000083	96.76	gold quality
minor salivary gland	UBERON:0001830	96.47	gold quality
mouth mucosa	UBERON:0003729	96.26	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.94	gold quality
saliva-secreting gland	UBERON:0001044	95.68	gold quality
lung	UBERON:0002048	95.55	gold quality
duodenum	UBERON:0002114	95.48	gold quality
superior surface of tongue	UBERON:0007371	95.01	gold quality
adult organism	UBERON:0007023	94.66	gold quality
bone marrow cell	CL:0002092	94.52	gold quality
nasal cavity mucosa	UBERON:0001826	94.28	gold quality
amniotic fluid	UBERON:0000173	93.64	gold quality
gingiva	UBERON:0001828	92.97	gold quality
parotid gland	UBERON:0001831	91.81	gold quality
sperm	CL:0000019	91.26	gold quality
tonsil	UBERON:0002372	91.15	gold quality
gingival epithelium	UBERON:0001949	91.07	gold quality
upper leg skin	UBERON:0004262	90.20	gold quality
vermiform appendix	UBERON:0001154	90.11	gold quality
male germ cell	CL:0000015	89.93	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	88.01	gold quality
caecum	UBERON:0001153	87.28	gold quality
transverse colon	UBERON:0001157	87.02	gold quality
vagina	UBERON:0000996	86.70	gold quality
skin of hip	UBERON:0001554	85.72	gold quality
buccal mucosa cell	CL:0002336	85.66	gold quality
upper arm skin	UBERON:0004263	85.52	gold quality
jejunum	UBERON:0002115	85.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.74	gold quality
periodontal ligament	UBERON:0008266	82.18	gold quality
pancreas	UBERON:0001264	81.55	gold quality
oviduct epithelium	UBERON:0004804	81.13	gold quality
mucosa of urinary bladder	UBERON:0001259	79.50	gold quality
large intestine	UBERON:0000059	79.36	gold quality
diaphragm	UBERON:0001103	78.81	gold quality
intestine	UBERON:0000160	78.73	gold quality
type B pancreatic cell	CL:0000169	78.57	silver quality
colon	UBERON:0001155	78.49	gold quality
olfactory bulb	UBERON:0002264	78.02	gold quality
monocyte	CL:0000576	77.46	gold quality
mononuclear cell	CL:0000842	77.08	gold quality
small intestine	UBERON:0002108	76.73	gold quality
endometrium epithelium	UBERON:0004811	76.15	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.85	gold quality
epithelium of mammary gland	UBERON:0003244	75.81	gold quality
mammary duct	UBERON:0001765	75.53	gold quality
leukocyte	CL:0000738	75.48	gold quality
zone of skin	UBERON:0000014	75.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	75.18	gold quality
uterine cervix	UBERON:0000002	74.98	gold quality
skin of leg	UBERON:0001511	74.36	gold quality
esophagus	UBERON:0001043	74.12	gold quality
blood	UBERON:0000178	73.62	gold quality
colonic epithelium	UBERON:0000397	73.51	gold quality
vastus lateralis	UBERON:0001379	73.46	gold quality
body of pancreas	UBERON:0001150	73.42	gold quality
fallopian tube	UBERON:0003889	73.32	gold quality
penis	UBERON:0000989	73.00	gold quality
quadriceps femoris	UBERON:0001377	72.89	gold quality
hair follicle	UBERON:0002073	72.84	gold quality
gluteal muscle	UBERON:0002000	71.76	gold quality
skin of abdomen	UBERON:0001416	71.65	gold quality
triceps brachii	UBERON:0001509	71.36	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-GEOD-86618	yes	6918.00
E-MTAB-9801	yes	2639.35
E-HCAD-15	yes	1916.79
E-MTAB-8530	yes	1894.19
E-MTAB-6653	yes	1209.55
E-MTAB-8410	yes	1037.31
E-CURD-114	yes	434.35
E-GEOD-125970	yes	26.83
E-HCAD-1	yes	22.52
E-GEOD-130148	yes	10.38
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

59 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Lung	tissue	270.1	medium
Rectum	tissue	206.9	medium
Colon	tissue	183.1	medium
Bone marrow	tissue	171.4	low
Esophagus	tissue	154.2	not detected
Gallbladder	tissue	122.2	low
Vagina	tissue	83.1	not detected
Salivary gland	tissue	42.5	not detected
Duodenum	tissue	31.1	not detected
Tonsil	tissue	30.5	low
Appendix	tissue	28.0	high
Small intestine	tissue	23.0	not detected
Stomach 1	tissue	14.7	low
Urinary bladder	tissue	9.0	not detected
Fallopian tube	tissue	7.8	not detected
Smooth muscle	tissue	6.2	not detected
Cervix	tissue	4.9	not detected
Basal ganglia	tissue	4.6	not detected
Putamen	tissue	4.6
Cerebellum	tissue	3.3	not detected
Skin 1	tissue	3.2	not detected
Cerebral cortex	tissue	3.1	not detected
Nucleus accumbens	tissue	3.1
Pancreas	tissue	2.9	not detected
Medulla oblongata	tissue	2.7
Amygdala	tissue	2.6
Breast	tissue	2.5	not detected
Pons	tissue	2.5
Occipital cortex	tissue	2.5
Thalamus	tissue	2.4
Hippocampal formation	tissue	2.4
Midbrain	tissue	2.3
Prostate	tissue	2.3	not detected
Hypothalamus	tissue	2.2
Retrosplenial cortex	tissue	2.2
Hippocampus	tissue	2.1	not detected
Thymus	tissue	2.0
Adipose tissue	tissue	1.9	not detected
Postcentral gyrus	tissue	1.9
Choroid plexus	tissue	1.8
Spinal cord	tissue	1.8
Epididymis	tissue	1.7	not detected
Locus coeruleus	tissue	1.7
Substantia nigra	tissue	1.4
Seminal vesicle	tissue	1.3	not detected
Spleen	tissue	0.7	low
Liver	tissue	0.7	not detected
Endometrium 1	tissue	0.5	not detected
Placenta	tissue	0.5	not detected
Testis	tissue	0.4	not detected
Adrenal gland	tissue	0.4	not detected
Lymph node	tissue	0.3	low
Kidney	tissue	0.3	not detected
Pituitary gland	tissue	0.2
Thyroid gland	tissue	0.2	not detected
Heart muscle	tissue	0.1	not detected
Parathyroid gland	tissue	0.1	not detected
Nasopharynx	tissue	-1.0	low
Bronchus	tissue	-1.0	low

Brain sub-regions (HPA Brain Atlas): detected in 186; highest nTPM — Flocculonodular lobe (3.3), Nucleus basalis of Meynert (3.2), Postcentral gyrus, ventral (3.1), Caudate nucleus (3.0), Posterior cingulate cortex (3.0).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1, GLI2, TCF7

miRNA regulators (miRDB)

Targeting CEACAM6 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 76 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4446-5P	99.72	69.19	2544

Functional genomics

gnomAD constraint: pLI 9.39e-05, LOEUF 0.908, missense Z 0.863 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000199764 — one region, missense o/e 0.94.

Literature-anchored findings (GeneRIF, showing 40)

• Overexpression of CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation (PMID:11896570)
• CEACAM6 subdomains involved in intercellular adhesion activity and subdomains involved in inhibition of cell differentation are identified and their respective activities are independently blocked. (PMID:12571231)
• the first study to demonstrate the prognostic relevance of CEACAM6 overexpression in human colorectal cancer (PMID:14512395)
• overexpression among human malignancies, immunological targeting of this tumor antigen may have therapeutic applicability (PMID:15081416)
• the results show that recognition of CEA and CEACAM6, but not CEACAM1, is accompanied by tight attachment to bacteria of cell surface microvilli-like extensions (PMID:15130118)
• CEACAM6 is an important determinant of pancreatic adenocarcinoma malignant cellular behavior (PMID:15208677)
• Levels of CEACAM6 expression can modulate pancreatic adenocarcinoma cellular invasiveness in a c-Src-dependent manner (PMID:15316565)
• CD66c is regulated in a manner distinct from other myeloid antigens in childhood lymphoblastic leukemia (PMID:15826304)
• Data show that variants of Neisseria gonorrhoeae that bind to human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 1 and 6 failed to induce detachment and, instead, promoted enhanced host cell adhesion to the ECM. (PMID:16115956)
• The expression of CEACAM6 in ADH lesions is strongly associated with the development of IBC, therefore, it can be applied as a diagnostic marker either singly or in combination with other marker(s) to predict IBC development in women with ADH lesions. (PMID:16899629)
• CEA and CEACAM6 was shown to lead to an increase in the binding of the integrin alpha5beta1 receptor to its ligand fibronectin, without changing its cell surface levels, resulting in increased adhesion of CEA/CEACAM6-expressing cells to fibronectin. (PMID:17167768)
• For all tumors, the amount of CEACAM6 expressed was greater than that of CEACAM5, and reflected tumor histotype. (PMID:17201906)
• CEA-mediated signaling involves clustering of CEA and co-clustering and activation of the alpha5beta1 and associated specific signaling elements on the internal surfaces of membrane microdomains (PMID:17286276)
• CEACAM6 is a biological tumor marker for epithelial ovarian cancers. (PMID:17503391)
• CEACAM6 acts as a receptor for adherent-invasive E. coli adhesion and is abnormally expressed by ileal epithelial cells in Crohn disease. (PMID:17525800)
• findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. (PMID:17653079)
• All the leukemic samples showed overexpression of CEACAM6 and 8 when compared with normal granulocytes. (PMID:17909799)
• data support an important role for CEACAM6 in endocrine resistance in breast cancer, which can serve as a powerful predictor of future recurrence (PMID:18223215)
• CEACAM6 is overexpressed in borderline and invasive mucinous ovarian neoplasms. (PMID:18331757)
• Data show that desensitization of neutrophils to any two CEACAMs, 1, 3, 6, or 8, results in selective desensitization to those two CEACAMs, while the cells remain responsive to the other two neutrophil CEACAMs. (PMID:19077207)
• Because CEACAM6 acts as an antiapoptotic factor and stabilizes surfactant function, in addition to a putative role in innate defense against bacteria, we propose that it is a multifunctional alveolar protein (PMID:19329538)
• CEACAM6-associated signaling pathways could be potential targets for the development of biomarkers to predict the response of patients to adenovirus-based therapies, as well as for the development of more potent adenovirus-based therapeutics (PMID:19411761)
• CEACAM6 and a regulatory element near the 3’ end of CEACAM3 are associated with cystic fibrosis disease severity and intrapair discordance (PMID:20047061)
• Positivity for both leukemia-associated antigens CD66c and CD25 in combination can predict the presence of BCR/ABL rearrangement in pre-B cell acute lymphoblastic leukemia (PMID:20063526)
• The highly elevated gene expression of CEACAM6 and CEACAM8 in primary myelofibrosis can serve as molecular markers of myelofibrotic transformation. (PMID:21470677)
• Despite its important role in bacterial attachment in ileal CD, no role was detected for CEACAM6 variants in IBD susceptibility or regarding an ileal CD phenotype (PMID:21559399)
• High serum CEACAM6 is associated with gastric cancer. (PMID:21618249)
• High CEACAM6 expresssion is associated with inflammatory bowel disease. (PMID:21994005)
• CEACAM6 is expressed by alveolar and airway epithelial cells of human lung and is secreted into lung-lining fluid, where fully glycosylated protein binds to surfactant. (PMID:22037359)
• The authors show that the expression of CEACAM1 and CEACAM6 potentiate CEACAM3-dependent responses of neutrophils, exposing a cooperative role for this family of proteins during neisserial infection of neutrophils. (PMID:22064717)
• a novel role for NA in enhancing host cell survival by activating the Src/Akt signaling axis via an interaction with carcinoembryonic antigen-related cell adhesion molecule 6/cluster of differentiation 66c (C6). (PMID:22396546)
• CEACAM6 is significantly upregulated in colon cancer tissues and is closely associated with poor prognosis. (PMID:22975528)
• CEACAM6 is focally overexpressed in a large fraction of human HNSCCs in situ. over-expression of CEACAM6 increases tumour growth and tumour initiating activity by suppressing PI3K/AKT-dependent apoptosis of HNSCC in a xenotransplant model of HNSCC. (PMID:23021083)
• The expression of CD66c was significantly higher in colorectal cancer specimens than in normal colon. (PMID:23027178)
• these findings show that PDEF-CEACAM6 is a highly active oncogenic axis in breast cancer (PMID:23592399)
• CEACAM-6 plays an important role in the regulation of CD8+ T-cell responses against multiple myeloma. (PMID:23603913)
• High carcinoembryonic cell adhesion molecule 6 expression is associated with malignant biliary stenoses. (PMID:23806607)
• our findings identified CEACAM6, which is regulated by miR-29a/b/c, as an important positive regulator of EMT in pancreatic cancer (PMID:23857344)
• CD66c expression appears useful only as a predictor of the Ph in adult patients (not in pediatric cases). (PMID:24014076)
• CEACAM6 expression was expressed in different molecular subtypes of breast cancer. Among different subtypes, the highest expression was found with HER2 positive cancers. (PMID:24186057)

Cross-species orthologs

36 orthologs

Organism	Symbol	Gene ID
mus_musculus	Psg18	ENSMUSG00000003505
mus_musculus	Psg17	ENSMUSG00000004540
mus_musculus	Psg19	ENSMUSG00000004542
mus_musculus	Ceacam5	ENSMUSG00000008789
mus_musculus	Psg29	ENSMUSG00000023159
mus_musculus	Ceacam14	ENSMUSG00000023185
mus_musculus	Ceacam12	ENSMUSG00000030366
mus_musculus	Ceacam11	ENSMUSG00000030368
mus_musculus	Psg28	ENSMUSG00000030373
mus_musculus	Psg22	ENSMUSG00000044903
mus_musculus	Ceacam3	ENSMUSG00000053228
mus_musculus	Ceacam10	ENSMUSG00000054169
mus_musculus	Ceacam2	ENSMUSG00000054385
mus_musculus	Ceacam13	ENSMUSG00000057195
mus_musculus	Psg20	ENSMUSG00000063305
mus_musculus	Psg16	ENSMUSG00000066760
mus_musculus	Psg21	ENSMUSG00000070796
mus_musculus	Psg27	ENSMUSG00000070797
mus_musculus	Psg25	ENSMUSG00000070798
mus_musculus	Psg26	ENSMUSG00000070799
mus_musculus	Ceacam1	ENSMUSG00000074272
mus_musculus	Psg23	ENSMUSG00000074359
mus_musculus	Ceacam23	ENSMUSG00000078793
rattus_norvegicus	LOC102557244	ENSRNOG00000017519
rattus_norvegicus	Ceacam11	ENSRNOG00000017620
rattus_norvegicus	Ceacam1	ENSRNOG00000020578
rattus_norvegicus	Psgb1	ENSRNOG00000027288
rattus_norvegicus	Ceacam3	ENSRNOG00000027607
rattus_norvegicus	Psg29	ENSRNOG00000029485
rattus_norvegicus	LOC120098290	ENSRNOG00000034000
rattus_norvegicus	Psg19	ENSRNOG00000038101
rattus_norvegicus	Ceacam12	ENSRNOG00000042158
rattus_norvegicus	Ceacam4	ENSRNOG00000046222
rattus_norvegicus	Psg16	ENSRNOG00000062379
rattus_norvegicus	Cgm4	ENSRNOG00000062787
rattus_norvegicus	LOC102557319	ENSRNOG00000071114

Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1347251) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 51 distinct phenotype terms.

Mouse phenotype (MP)	Records
increased circulating insulin level	2
decreased mean corpuscular hemoglobin concentration	2
decreased susceptibility to Coronaviridae infection	2
increased leukocyte cell number	1
abnormal colon morphology	1
obese	1
polyphagia	1
increased circulating HDL cholesterol level	1
decreased litter size	1
abnormal coat/hair pigmentation	1
abnormal glucose homeostasis	1
decreased susceptibility to viral infection	1
abnormal T cell physiology	1
increased mean platelet volume	1
decreased circulating triglyceride level	1
abnormal cytokine secretion	1
decreased circulating chloride level	1
increased insulin secretion	1
increased lean body mass	1
increased incidence of tumors by chemical induction	1
abnormal vascular wound healing	1
decreased energy expenditure	1
decreased T cell number	1
decreased T cell proliferation	1
decreased circulating cholesterol level	1

+26 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo pygmaeus	Q9N1E3	92.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
CEACAM5	protein-coding	1048
CEACAM3	protein-coding	1084
LYPD4	protein-coding	147719
CEACAM7	protein-coding	1087
DMRTC2	protein-coding	63946

Protein

Protein identifiers

Cell adhesion molecule CEACAM6 — P40199 (reviewed: P40199)

Alternative names: Carcinoembryonic antigen-related cell adhesion molecule 6, Non-specific crossreacting antigen, Normal cross-reacting antigen

All UniProt accessions (2): P40199, M0QYD3

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface glycoprotein that plays a role in cell adhesion and tumor progression. Intercellular adhesion occurs in a calcium- and fibronectin-independent manner. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8. Heterophilic interaction with CEACAM8 occurs in activated neutrophils. Plays a role in neutrophil adhesion to cytokine-activated endothelial cells. Plays a role in cell migration and cell adhesion to endothelial cells.

Subunit / interactions. Homodimer; homodimerizes via its Ig-like V-type domain. Heterodimer with CEACAM8; heterodimerizes via its Ig-like V-type domain.

Subcellular location. Cell membrane. Apical cell membrane. Cell surface.

Tissue specificity. Expressed in neutrophils. Expressed in columnar epithelial and goblet cells of the colon. Expressed in numerous tumor cell lines (at protein level).

Post-translational modifications. Glycosylated.

Domain organisation. The extracellular N-terminus Ig-like V-type domain is necessary for homophilic and heterophilic intercellular adhesion.

Similarity. Belongs to the immunoglobulin superfamily. CEA family.

RefSeq proteins (1): NP_002474* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050831	CEA_cell_adhesion	Family

Pfam: PF07686, PF13895, PF13927

UniProt features (45 total): glycosylation site 12, mutagenesis site 10, strand 9, domain 3, disulfide bond 2, helix 2, signal peptide 1, chain 1, propeptide 1, sequence variant 1, sequence conflict 1, turn 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

6 structures by resolution:

PDB	Title	Method	Resolution (Å)
4Y8A	Crystal Structure of the N-terminal domain of CEACAM6	X-RAY DIFFRACTION	1.83
4YIQ	Structure of the CEACAM6-CEACAM8 heterodimer	X-RAY DIFFRACTION	1.85
4WTZ	Human CEACAM6-CEACAM8 N-domain heterodimer complex	X-RAY DIFFRACTION	2.52
4WHC	Human CEACAM6 N-domain	X-RAY DIFFRACTION	2.71
9RCU	Cardioderma bat coronavirus 2B receptor binding domain in complex with human CEACAM6	X-RAY DIFFRACTION	2.99
9RCS	Cardioderma bat coronavirus KY43 receptor binding domain in complex with human CEACAM6	X-RAY DIFFRACTION	3.01

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P40199-F1	88.52	0.83

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Predicted intracellular proteins, Cancer-related genes, Candidate cancer biomarkers

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH enhanced

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Gpi-anchor amidated glycine	320

Disulfide bonds (2)

Type	Positions
Disulfide bond	167–215, 259–299

Glycosylation sites (12)

Type	Positions
N-linked (glcnac…) asparagine	152, 173, 197, 224, 256, 274, 288, 292, 309, 104, 111, 115

Mutagenesis-validated functional residues (10)

Position	Phenotype
38	loss of homodimerization and heterodimerization with ceacam8.
53	no effect on homodimerization. reduces heterodimerization with ceacam8.
55	no effect on homophilic and heterophilic cell adhesion.
61	inhibits homophilic and heterophilic cell adhesion.
62	no effect on homophilic cell adhesion. reduces heterophilic cell adhesion.
63	no effect on homophilic cell adhesion. inhibits heterophilic cell adhesion.
66	inhibits homophilic cell adhesion. reduces heterophilic cell adhesion.
78	inhibits homophilic cell adhesion. no effect on heterophilic cell adhesion.
123	no effect on homodimerization. reduces heterodimerization with ceacam8.
129	reduces homodimerization. loss of heterodimerization with ceacam8.

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 7; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

7 pathways:

ID	Pathway	Evidence
R-HSA-202733	Cell surface interactions at the vascular wall	curated
R-HSA-1566977	Fibronectin matrix formation	curated
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-1474244	Extracellular matrix organization	—
R-HSA-109582	Hemostasis	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—

MSigDB gene sets: 282 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, MODULE_92, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOCC_VACUOLAR_MEMBRANE, GOCC_SECRETORY_GRANULE, GOBP_REGULATION_OF_HETEROTYPIC_CELL_CELL_ADHESION, GOZGIT_ESR1_TARGETS_DN, GOCC_CELL_SURFACE, CROONQUIST_NRAS_SIGNALING_UP, ONDER_CDH1_TARGETS_3_DN, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_POSITIVE_REGULATION_OF_CELL_MATRIX_ADHESION

GO Biological Process (9): apoptotic process (GO:0006915), homophilic cell-cell adhesion (GO:0007156), heterophilic cell-cell adhesion (GO:0007157), positive regulation of cell population proliferation (GO:0008284), positive regulation of cell migration (GO:0030335), positive regulation of heterotypic cell-cell adhesion (GO:0034116), positive regulation of endothelial cell-matrix adhesion (GO:1904906), negative regulation of anoikis (GO:2000811), cell adhesion (GO:0007155)

GO Molecular Function (3): identical protein binding (GO:0042802), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020), apical plasma membrane (GO:0016324), azurophil granule membrane (GO:0035577), side of membrane (GO:0098552)

Reactome top-level categories

4 top-level categories:

Category	Pathways
Extracellular matrix organization	1
Hemostasis	1
Innate Immune System	1
Immune System	1

GO top-level categories

32 GO namespaces:

Category	Terms
cellular anatomical structure	3
cell-cell adhesion	2
membrane	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
positive regulation of cell-cell adhesion	1
heterotypic cell-cell adhesion	1
regulation of heterotypic cell-cell adhesion	1
positive regulation of cell-matrix adhesion	1
endothelial cell-matrix adhesion	1
regulation of endothelial cell-matrix adhesion	1
negative regulation of apoptotic process	1
anoikis	1
regulation of anoikis	1
cellular process	1
protein binding	1
protein dimerization activity	1
binding	1
cell periphery	1
apical part of cell	1
plasma membrane region	1
lysosomal membrane	1
secretory granule membrane	1
azurophil granule	1
leaflet of membrane bilayer	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 12 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).

12 experimentally-supported GO terms:

GO term	NS	Evidence
heterophilic cell-cell adhesion	BP	mutant phenotype
homophilic cell-cell adhesion	BP	mutant phenotype
negative regulation of anoikis	BP	mutant phenotype
positive regulation of cell migration	BP	mutant phenotype
positive regulation of cell population proliferation	BP	mutant phenotype
positive regulation of endothelial cell-matrix adhesion	BP	mutant phenotype
positive regulation of heterotypic cell-cell adhesion	BP	mutant phenotype
apical plasma membrane	CC	direct assay
cell surface	CC	direct assay
membrane	CC	direct assay
identical protein binding	MF	direct assay
protein heterodimerization activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,392 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEACAM6	A1BG	P04217	547
CEACAM6	MUC4	Q99102	537
CEACAM6	TACSTD2	P09758	513
CEACAM6	MUC5B	Q9HC84	499
CEACAM6	MUC5AC	P98088	498
CEACAM6	MUC13	Q9H3R2	487
CEACAM6	MUC17	Q685J3	464
CEACAM6	CYTH4	Q9UIA0	463
CEACAM6	DEFA4	P12838	450
CEACAM6	MUC2	Q02817	449
CEACAM6	MUC20	Q8N307	430
CEACAM6	DEFA5	Q01523	412
CEACAM6	DEFA6	Q01524	412
CEACAM6	ERV3-1	Q14264	410
CEACAM6	ERVFRD-1	P60508	409

IntAct

Human interaction partners of CEACAM6 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 31 partners by confidence:

Partner	Interaction type	MIscore	Records
CEACAM8	direct interaction	0.820	8
CEACAM1	physical association	0.610	3
MSS51	physical association	0.560	5
UBQLN2	physical association	0.560	5
ASPG	physical association	0.560	3
CIB1	physical association	0.560	3
CSTF2	physical association	0.560	3
EXOC3L1	physical association	0.560	3
FOXH1	physical association	0.560	3
GCM2	physical association	0.560	3
GPANK1	physical association	0.560	3
HGS	physical association	0.560	3
HPCAL4	physical association	0.560	3
KANK2	physical association	0.560	3
MYOZ1	physical association	0.560	3
PITX1	physical association	0.560	3
POM121	physical association	0.560	3
QRICH1	physical association	0.560	3
RHOXF2	physical association	0.560	3
SHC3	physical association	0.560	3
SMARCD1	physical association	0.560	3
TLX3	physical association	0.560	3
TNXB	physical association	0.560	3
VENTX	physical association	0.560	3
VEZF1	physical association	0.560	3
WWOX	physical association	0.560	3
ZMYND19	physical association	0.560	3
ZNF76	physical association	0.560	3
CARTPT	physical association	0.540	3
CEACAM5	physical association	0.400	1

BioGRID (269 interactions; top human partners by supporting records): ITGA2 (Proximity Label-MS; 3 records), ITGB1 (Proximity Label-MS; 3 records), PRKCD (Proximity Label-MS; 3 records), CEACAM1 (Reconstituted Complex; 2 records), ABHD12 (Proximity Label-MS), ACACA (Proximity Label-MS), ACBD5 (Proximity Label-MS), ACSL4 (Proximity Label-MS), AGPAT6 (Proximity Label-MS), AGPAT9 (Proximity Label-MS), ALDH3A2 (Proximity Label-MS), ALG9 (Proximity Label-MS), ANKLE2 (Proximity Label-MS), ANO10 (Proximity Label-MS), ANO6 (Proximity Label-MS)

Ligand–receptor pairs (CellPhoneDB) (4)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

4 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
CEACAM6	ligand	Adhesion by CEAM
CEACAM5	receptor	Adhesion by CEAM
CEACAM8	receptor	Adhesion by CEAM
CEACAM1	receptor	Adhesion by CEAM

Disease & clinical

Genetic variants

Variant evidence for CEACAM6: 53 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	41
Likely benign	7
Benign	2

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 312):

Position(s)	Effect	Δscore	Sites
19:41755703	donor_loss	1.0000
19:41755703–41755704	donor_loss	0.9900	3
19:41756598–41756599	acceptor_loss	0.9900	6
19:41761246	acceptor_gain	0.9900
19:41761247–41761248	acceptor_loss	0.9900	6
19:41761528–41761529	donor_loss	0.9900	5
19:41769664	donor_gain	0.9900
19:41755704	donor_loss	0.9800
19:41756960–41756961	donor_loss	0.9800	5
19:41756964	donor_loss	0.9800	2

AlphaMissense

207 missense substitutions predicted likely pathogenic (of 2,224 scored), across 74 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
W67	7	0.861	0.956
C299	7	0.849	0.942
C259	7	0.848	0.913
C215	7	0.845	0.941
W271	7	0.838	0.939
C167	7	0.828	0.884
W178	6	0.853	0.935
S226	6	0.809	0.941
D116	6	0.640	0.678
N303	5	0.735	0.895
G92	5	0.727	0.766
F138	5	0.726	0.796
Y297	5	0.717	0.898
G236	4	0.751	0.815
S263	4	0.750	0.824
Y120	4	0.749	0.906
Y213	4	0.721	0.873
Y269	4	0.681	0.754
G118	4	0.589	0.619
L107	3	0.827	0.939

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Lung Adenocarcinoma, Rectum Adenocarcinoma)

Disease associations

OMIM: gene MIM:163980 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
cystic fibrosis	Supportive	Autosomal recessive

Mondo (1): cystic fibrosis (MONDO:0009061)

HPO phenotypes

35 phenotypes (HPO-id order):

HPO	Term
HP:0000246	Sinusitis
HP:0000365	Hearing impairment
HP:0000716	Depression
HP:0000739	Anxiety
HP:0000787	Kidney stone
HP:0000938	Osteopenia
HP:0000939	Osteoporosis
HP:0001392	Abnormality of the liver
HP:0001394	Cirrhosis
HP:0001508	Failure to thrive
HP:0001738	Exocrine pancreatic insufficiency
HP:0002020	Gastroesophageal reflux
HP:0002024	Malabsorption
HP:0002035	Rectal prolapse
HP:0002099	Asthma
HP:0002105	Hemoptysis
HP:0002107	Pneumothorax
HP:0002110	Bronchiectasis
HP:0002205	Recurrent respiratory infections
HP:0002570	Steatorrhea
HP:0002724	Recurrent Aspergillus infection
HP:0002726	Recurrent Staphylococcus aureus infection
HP:0002783	Recurrent lower respiratory tract infections
HP:0002842	Recurrent Burkholderia cepacia infection
HP:0002910	Elevated circulating hepatic transaminase concentration
HP:0003251	Male infertility
HP:0004401	Meconium ileus
HP:0005376	Recurrent Haemophilus influenzae infection
HP:0006536	Airway obstruction
HP:0012236	Elevated sweat chloride
HP:0012873	Absent vas deferens
HP:0032261	Nontuberculous mycobacterial pulmonary infection
HP:0032342	Reduced forced expiratory volume in one second
HP:0045082	Decreased body mass index
HP:0100582	Nasal polyposis

GWAS associations

1 associations:

Study	Trait	p-value
GCST009650_9	Serum carcinoembryonic antigen levels	5e-10

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0005760	serum carcinoembryonic antigen measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D003550	Cystic Fibrosis	C06.689.202; C08.381.187; C16.320.190; C16.614.213

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects cotreatment, affects expression, increases expression, increases methylation	3
Estradiol	affects cotreatment, increases expression, decreases expression	3
Calcitriol	increases expression	2
Lipopolysaccharides	affects expression, affects response to substance, affects cotreatment, decreases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	increases expression	2
Cadmium Chloride	increases expression, decreases expression, increases abundance	2
ascorbate-2-phosphate	affects binding, affects cotreatment, increases expression	1
pyrazolo(3,4-d)pyrimidine	affects expression	1
beta-lapachone	increases expression	1
zinc chloride	increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
tetrathiomolybdate	decreases expression	1
tanshinone	decreases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, decreases expression	1
1-methylphenanthrene	affects expression, affects cotreatment	1
dibenzo(a,l)pyrene	affects cotreatment, affects expression	1
tamibarotene	increases expression, increases reaction, decreases expression, decreases reaction	1
indolo(3,2-b)carbazole	increases expression	1
CGP 52608	affects binding, increases reaction	1
azaspiracid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
Chir 99021	affects cotreatment, increases expression, affects binding	1
clothianidin	increases expression	1
abrine	decreases expression	1
XAV939	affects binding, affects cotreatment, increases expression	1

Cellosaurus cell lines

3 cell lines: 2 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C0EK	HEK293-CEACAM6-Fc	Transformed cell line	Female
CVCL_E6PX	Genomeditech CHO-K1 H_CEACAM6(CD66c)	Spontaneously immortalized cell line	Female
CVCL_E6TL	Genomeditech HEK-293 H_CEACAM6(CD66c)	Transformed cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00157690	Phase 4	COMPLETED	Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
NCT00208078	Phase 4	TERMINATED	Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00244270	Phase 4	COMPLETED	Cystic Fibrosis and Totally Implantable Vascular Access Devices
NCT00333385	Phase 4	TERMINATED	Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
NCT00411736	Phase 4	COMPLETED	Scandinavian Cystic Fibrosis Azithromycin Study
NCT00418470	Phase 4	TERMINATED	Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People
NCT00431964	Phase 4	COMPLETED	Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
NCT00434278	Phase 4	TERMINATED	A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
NCT00483769	Phase 4	COMPLETED	One Year Glargine Treatment in CFRD Children and Adolescents
NCT00528190	Phase 4	COMPLETED	Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
NCT00557089	Phase 4	COMPLETED	The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
NCT00572975	Phase 4	COMPLETED	Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
NCT00680316	Phase 4	TERMINATED	A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
NCT00685035	Phase 4	COMPLETED	Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
NCT00744250	Phase 4	TERMINATED	Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
NCT00787917	Phase 4	TERMINATED	An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
NCT00843817	Phase 4	COMPLETED	RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
NCT00890370	Phase 4	COMPLETED	Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?
NCT00996424	Phase 4	TERMINATED	The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function
NCT01044719	Phase 4	UNKNOWN	Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
NCT01100606	Phase 4	COMPLETED	A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
NCT01131507	Phase 4	COMPLETED	PR-018: An Open-Label, Safety Extension of Study PR-011
NCT01207245	Phase 4	COMPLETED	Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis
NCT01323101	Phase 4	COMPLETED	Doxycycline Effects on Inflammation in Cystic Fibrosis
NCT01327703	Phase 4	COMPLETED	Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
NCT01377792	Phase 4	COMPLETED	Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
NCT01400750	Phase 4	COMPLETED	Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis
NCT01429259	Phase 4	COMPLETED	Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
NCT01608555	Phase 4	COMPLETED	Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
NCT01667094	Phase 4	UNKNOWN	A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
NCT01694069	Phase 4	TERMINATED	Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
NCT01702415	Phase 4	WITHDRAWN	Zoledronic Acid in Cystic Fibrosis
NCT01712334	Phase 4	COMPLETED	A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
NCT01737983	Phase 4	COMPLETED	Effect of Lactobacillus Reuteri in Cystic Fibrosis
NCT01844778	Phase 4	COMPLETED	Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
NCT01880346	Phase 4	COMPLETED	Comparison of Absorption of Vitamin D in Cystic Fibrosis
NCT01882400	Phase 4	COMPLETED	Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
NCT01937325	Phase 4	UNKNOWN	CPET in CF Patients With One G551D Mutation Taking VX770
NCT02015663	Phase 4	TERMINATED	Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
NCT02048592	Phase 4	UNKNOWN	Impact of Immunonutrition on the Patients With Cystic Fibrosis
NCT02178540	Phase 4	COMPLETED	Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
NCT02277626	Phase 4	COMPLETED	Electro Flo 5000 and Vest Therapy
NCT02421120	Phase 4	COMPLETED	Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
NCT02444234	Phase 4	COMPLETED	Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
NCT02504827	Phase 4	COMPLETED	Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis
NCT02547116	Phase 4	WITHDRAWN	Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
NCT02677701	Phase 4	COMPLETED	Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
NCT02700282	Phase 4	COMPLETED	Backpack Carrying in Children With Cystic Fibrosis
NCT02823470	Phase 4	TERMINATED	A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
NCT02823964	Phase 4	COMPLETED	EASY: Extended Access to Sollpura Over Years
NCT02875366	Phase 4	COMPLETED	A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
NCT02894684	Phase 4	COMPLETED	Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
NCT02918409	Phase 4	COMPLETED	IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
NCT03045198	Phase 4	UNKNOWN	Effect of Azithromycin on Fatty Acids in CF
NCT03172793	Phase 4	COMPLETED	Telavancin Pharmacokinetics in Cystic Fibrosis Patients
NCT03256799	Phase 4	COMPLETED	Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
NCT03256968	Phase 4	COMPLETED	PTC Study to Evaluate Ataluren in Combination With Ivacaftor
NCT03502070	Phase 4	COMPLETED	Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
NCT03624101	Phase 4	TERMINATED	Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
NCT03632525	Phase 4	COMPLETED	Intravenous Iron in Adults With Cystic Fibrosis